Multiple system atrophy

7 trials 2 recruiting MedDRA PT
7 Registered trials
2 Recruiting
7 Unique sponsors
3 Unique IMPs
7 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Monoclonal antibody (neural) 1 substance
Phase III: 1 Phase II: 2 Phase I: 3 Phase I (Other): 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

1 trial
  • H. Lundbeck A/S Commercial
    AMLENETUG
    2024-517169-18-00 5 countries 2025 n=140 Orphan
    Ended

Phase II

2 trials
  • BioArctic AB Commercial
    EXIDAVNEMAB
    2024-511222-30-00 2 countries 2024 n=36 Orphan
    Ended
  • Takeda Development Center Americas Inc. Commercial
    HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN
    2023-509876-40-00 7 countries 2022 n=101
    Ended

Phase I

3 trials
  • AC Immune S.A. Commercial
    IMP not specified
    2024-515664-31-00 1 country 2025 n=46
    Recruiting
  • Ionis Pharmaceuticals Inc. Commercial
    IMP not specified
    2024-512528-13-00 4 countries 2020 n=65
    Recruiting
  • Modag GmbH Commercial
    IMP not specified
    2023-506965-72-00 1 country n=28
    Pending

Phase I (Other)

1 trial
  • Teva Branded Pharmaceutical Products R&D LLC Commercial
    IMP not specified
    2024-515556-20-00 1 country 2024 n=8
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AC Immune S.A. Commercial 1 Phase I 1
Ionis Pharmaceuticals Inc. Commercial 1 Phase I 1
Modag GmbH Commercial 1 Phase I 0
Teva Branded Pharmaceutical Products R&D LLC Commercial 1 Phase I (Other) 0
BioArctic AB Commercial 1 Phase II 0
Takeda Development Center Americas Inc. Commercial 1 Phase II 0
H. Lundbeck A/S Commercial 1 Phase III 0
New trials by year
2020
1
2022
1
2024
2
2025
2
← All indication landscapes